Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension

Journal of Hypertension

Volumn 32, Issue 3, 2014, Pages 635-643

  Smith, Steven M ^a   Gong, Yan ^b   Handberg, Eileen ^c   Messerli, Franz H ^d   Bakris, George L ^e   Ahmed, Ali ^f   Bavry, Anthony A ^c   Pepine, Carl J ^c   Cooper Dehoff, Rhonda M ^b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e RUSH UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Blood pressure; Coronary artery disease; Hypertension; INVEST; Resistant hypertension

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEGRO; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RESISTANT HYPERTENSION; UNITED STATES;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84894044279     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000051     Document Type: Article

References (27)

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
2. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse north american settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404.
3. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR, ASCOT Investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011; 29:2004-2013.
4. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
5. Smith SM. Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy 2013; 33:1071-1086.
6. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-1080.
7. Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens 2013; 31:2018-2024.
8. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422-1428.
9. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125:1635-1642.
10. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34:1204-1214.
11. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease study 2010. Lancet 2012; 380:2095-2128.
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
13. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper- DeHoff R, Volkers P, Zellig P. Rationale and design of the international verapamil sr/trandolapril study (INVEST): an internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 1998; 32:1228-1237.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
15. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
16. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 2013; 112:255-259.
17. Dudenbostel T, Glasser SP. Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev 2012; 20:259-263.
18. Williams B. Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity-mortality. J Hypertens 2012; 30 (Suppl): S13-18.
19. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
20. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118-123.
21. Paulis L, Simko F. Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 2007; 56:671-684.
22. Kario K. Are melatonin and its receptor agonist specific antihypertensive modulators of resistant hypertension caused by disrupted circadian rhythm? J Am Soc Hypertens 2011; 5:354-358.
23. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43:192-197.
24. Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, et al. Cardiovascular outcomes in hypertensive patients: comparing singleagent therapy with combination therapy. J Hypertens 2012; 30:2213-2222.
25. Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol 2010; 108:227-237.
26. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60:1956-1965.
27. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34:2159-2219.